Article
Cardiac & Cardiovascular Systems
Benjamin E. Peterson, Deepak L. Bhatt, Ph Gabriel Steg, Michael Miller, Eliot A. Brinton, Terry A. Jacobson, Steven B. Ketchum, Rebecca A. Juliano, Lixia Jiao, Ralph T. Doyle, Craig Granowitz, C. Michael Gibson, Duane Pinto, Robert P. Giugliano, Matthew J. Budoff, Jean-Claude Tardif, Subodh Verma, Christie M. Ballantyne
Summary: Icosapent ethyl reduces the need for coronary revascularizations in patients with elevated triglycerides and increased cardiovascular risk who are receiving statin therapy, showing significant reduction in first and subsequent revascularizations as well as coronary artery bypass grafting.
Article
Cardiac & Cardiovascular Systems
Arjun Majithia, Deepak L. Bhatt, Allon N. Friedman, Michael Miller, Ph Gabriel Steg, Eliot A. Brinton, Terry A. Jacobson, Steven B. Ketchum, Rebecca A. Juliano, Lixia Jiao, Ralph T. Doyle, Craig Granowitz, Matthew Budoff, R. Preston Mason, Jean-Claude Tardif, William E. Boden, Christie M. Ballantyne
Summary: In the REDUCE-IT trial, icosapent ethyl reduced fatal and nonfatal ischemic events across a broad range of baseline eGFR categories.
Article
Cardiac & Cardiovascular Systems
Senthil Selvaraj, Deepak L. Bhatt, Ph Gabriel Steg, Michael Miller, Eliot A. Brinton, Terry A. Jacobson, Rebecca A. Juliano, Lixia Jiao, Jean-Claude Tardif, Christie M. Ballantyne
Summary: This study aimed to investigate the treatment effects of icosapent ethyl in patients with heart failure (HF). The results showed that icosapent ethyl reduced triglyceride and hs-CRP levels in patients with HF, and had similar cardiovascular risk reduction effects.
JOURNAL OF THE AMERICAN HEART ASSOCIATION
(2022)
Review
Cardiac & Cardiovascular Systems
Peter P. Toth, Jean Ferrieres, Max Waters, Martin Bodtker Mortensen, Nick S. R. Lan, Nathan D. Wong
Summary: This review summarizes the eligibility and cost effectiveness studies of IPE conducted to date. Sixteen studies with 2,068,111 patients in primary or secondary prevention settings worldwide were included. The proportion of patients eligible for IPE ranged from 15% to 45%, depending on the selection criteria and population studied. Overall, eight cost-effectiveness studies from the US, Canada, Germany, Israel, and Australia indicated that IPE is particularly cost effective in patients with established CVD.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2023)
Article
Cardiac & Cardiovascular Systems
Brian Olshansky, Deepak L. L. Bhatt, Michael Miller, Ph. Gabriel Steg, Eliot A. A. Brinton, Terry A. A. Jacobson, Steven B. B. Ketchum, Ralph T. T. Doyle Jr, Rebecca A. A. Juliano, Lixia Jiao, Peter R. R. Kowey, James A. A. Reiffel, Jean-Claude Tardif, Christie M. M. Ballantyne, Mina K. K. Chung
Summary: In the REDUCE-IT study, icosapent ethyl (IPE) reduced cardiovascular events but was associated with increased atrial fibrillation/atrial flutter (AF) hospitalization. The study analyzed the relationships between IPE and outcomes in patients with or without prior AF and with or without in-study AF hospitalization. Overall, in-study AF hospitalization rates were higher in patients with prior AF, especially in those randomized to IPE. Serious bleeding rates also trended higher in these patients. However, patients with prior AF or in-study AF hospitalization showed consistent risk reductions in cardiovascular events with IPE.
JOURNAL OF THE AMERICAN HEART ASSOCIATION
(2023)
Review
Pharmacology & Pharmacy
M. John Chapman, Jose L. Zamorano, Klaus G. Parhofer
Summary: Atherosclerotic cardiovascular disease (ASCVD) imposes a significant burden on Europe, and hypertriglyceridemia is a major risk factor for premature ASCVD. Recent studies have shown a correlation between elevated triglyceride levels and subclinical atherosclerosis and arterial inflammation. Icosapent ethyl (IPE) is a drug that can reduce the risk of cardiovascular events in patients with high triglyceride levels, possibly through triglyceride reduction and improvement of vascular function.
PHARMACOLOGY & THERAPEUTICS
(2022)
Review
Medicine, General & Internal
Ashish Gupta, Mohammad Alkhalil
Summary: Omega-3 polyunsaturated fatty acids (PUFAs) have been established as a therapeutic option for patients with high triglyceride levels. They have effects on lipoprotein particles and can be incorporated within the cellular membrane, leading to plaque stability and anti-inflammatory effects. However, recent clinical trials have shown inconsistent results regarding the cardioprotective effects of omega-3 fatty acids.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Cardiac & Cardiovascular Systems
Benjamin E. Peterson, Deepak L. Bhatt, Ph Gabriel Steg, Michael Miller, Eliot A. Brinton, Terry A. Jacobson, Steven B. Ketchum, Rebecca A. Juliano, Lixia Jiao, Ralph T. Doyle, Craig Granowitz, C. Michael Gibson, Duane Pinto, Robert P. Giugliano, Matthew J. Budoff, Jean-Claude Tardif, Subodh Verma, Christie M. Ballantyne
Summary: Icosapent Ethyl significantly reduces the risk of recurrent cardiovascular events in patients with elevated triglycerides and a history of prior percutaneous coronary intervention.
JOURNAL OF THE AMERICAN HEART ASSOCIATION
(2022)
Review
Cardiac & Cardiovascular Systems
Jessica Huston, Hannah Schaffner, Alyssa Cox, Alexander Sperry, Shelby Mcgee, Payeng Lor, Logan Langley, Blake Skrable, Majdi Ashchi, Mohannad Bisharat, Ashwini Gore, Thomas Jones, David Sutton, Mae Sheikh-Ali, Jason Berner, Rebecca Goldfaden
Summary: Icosapent ethyl (IPE) is the first fish oil product approved by the US FDA to reduce the risk of ASCVD in adults. It acts as a prodrug in the body and primarily reduces TG levels. Various studies and subanalyses have investigated the effects of IPE, including its impact on different patient groups and inflammatory biomarkers. This article critically reviews the clinical data on the cardiovascular benefits of IPE in ASCVD patients and its value as a treatment option for elevated TG levels.
AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS
(2023)
Article
Cardiac & Cardiovascular Systems
Subodh Verma, Deepak L. Bhatt, Ph Gabriel Steg, Michael Miller, Eliot A. Brinton, Terry A. Jacobson, Nitish K. Dhingra, Steven B. Ketchum, Rebecca A. Juliano, Lixia Jiao, Ralph T. Doyle, Craig Granowitz, C. Michael Gibson, Duane Pinto, Robert P. Giugliano, Matthew J. Budoff, R. Preston Mason, Jean-Claude Tardif, Christie M. Ballantyne
Summary: In patients with a history of coronary artery bypass grafting, treatment with icosapent ethyl in the REDUCE-IT trial led to significant reductions in both first and recurrent ischemic events compared to placebo, with similar safety findings between groups.
Review
Medicine, General & Internal
Kamini Trivedi, Viet Le, John R. Nelson
Summary: The FDA recently approved high-purity IPE, a prescription fish oil-derived omega-3 fatty acid, for CVD prevention in high-risk patients based on the 25% reduction in CVD event risk observed in the REDUCE-IT trial. IPE, compared to mixed omega-3 products, has shown to be a stable, highly purified formulation with FDA approval, making it an effective choice for CV prevention.
POSTGRADUATE MEDICINE
(2021)
Review
Pharmacology & Pharmacy
Manan Pareek, R. Preston Mason, Deepak L. Bhatt
Summary: In high cardiovascular risk patients, residual hypertriglyceridemia remains a significant contributor to elevated event rates despite traditional lipid-lowering therapy. Icosapent ethyl, a highly purified ethyl ester of eicosapentaenoic acid, has been shown to effectively reduce cardiovascular events in these patients, especially when triglyceride levels remain high despite statin treatment. Omega-3 fatty acid preparations containing a mix of eicosapentaenoic acid and docosahexaenoic acid are not recommended for reducing cardiovascular risk.
EXPERT OPINION ON DRUG SAFETY
(2022)
Review
Biochemistry & Molecular Biology
Assunta Di Costanzo, Ciro Indolfi, Sabato Sorrentino, Giovanni Esposito, Carmen Anna Maria Spaccarotella
Summary: This review examines the interaction between dyslipidemia, platelet function, and drug treatments. It provides an overview of the effects of hypolipidemic drugs on platelet function and discusses the role of statins, ezetimibe, PCSK9 inhibitors, inclisiran, and icosapent ethyl as antithrombotics. The review also highlights the importance of cholesterol-lowering therapy in reducing cardiovascular events.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Review
Cardiac & Cardiovascular Systems
Ronald M. Goldenberg, Alice Y. Y. Cheng, Jeremy D. Gilbert, Eva M. Lonn, Sue D. Pedersen, Subodh Verma
Summary: High triglyceride levels are associated with heightened cardiovascular risk, despite LDL-C levels and statin therapy. The REDUCE-IT trial with IPE demonstrated reduced cardiovascular risk in individuals with preexisting atherosclerotic cardiovascular disease or diabetes.
CURRENT OPINION IN CARDIOLOGY
(2021)
Review
Pharmacology & Pharmacy
Prakriti Gaba, Deepak L. Bhatt, R. Preston Mason, Michael Miller, Subodh Verma, Ph Gabriel Steg, William E. Boden
Summary: This article reviews the key findings of the REDUCE-IT trial and its subsequent analyses, highlighting the efficacy of IPE in high-risk cardiovascular patients, and calls for its inclusion in current guidelines.
JOURNAL OF CLINICAL LIPIDOLOGY
(2022)